AR008618A1 - PROCEDIMENTO PARA LA PREPARACIoN DE UNA FORMA SoLIDA COMPRIMIDA DE DOSIFICACIoN ORAL Y PROCEDIMIENTO PARA LA PREPARACIoN DE UN MATERIAL COMPACTADO DE GRANULACIoN GRUESA SIN COHESIoN ADECUADO PARA MÉTODOS ULTERIORES DE MOLIENDA Y COMPRESIoN ("COPRIMATE"). - Google Patents

PROCEDIMENTO PARA LA PREPARACIoN DE UNA FORMA SoLIDA COMPRIMIDA DE DOSIFICACIoN ORAL Y PROCEDIMIENTO PARA LA PREPARACIoN DE UN MATERIAL COMPACTADO DE GRANULACIoN GRUESA SIN COHESIoN ADECUADO PARA MÉTODOS ULTERIORES DE MOLIENDA Y COMPRESIoN ("COPRIMATE").

Info

Publication number
AR008618A1
AR008618A1 ARP970102790A ARP970102790A AR008618A1 AR 008618 A1 AR008618 A1 AR 008618A1 AR P970102790 A ARP970102790 A AR P970102790A AR P970102790 A ARP970102790 A AR P970102790A AR 008618 A1 AR008618 A1 AR 008618A1
Authority
AR
Argentina
Prior art keywords
procedure
preparation
oral dosage
coprimate
solid
Prior art date
Application number
ARP970102790A
Other languages
English (en)
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10795969&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR008618(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR008618A1 publication Critical patent/AR008618A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ARP970102790A 1996-06-27 1997-06-25 PROCEDIMENTO PARA LA PREPARACIoN DE UNA FORMA SoLIDA COMPRIMIDA DE DOSIFICACIoN ORAL Y PROCEDIMIENTO PARA LA PREPARACIoN DE UN MATERIAL COMPACTADO DE GRANULACIoN GRUESA SIN COHESIoN ADECUADO PARA MÉTODOS ULTERIORES DE MOLIENDA Y COMPRESIoN ("COPRIMATE"). AR008618A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9613470.5A GB9613470D0 (en) 1996-06-27 1996-06-27 Small solid oral dosage form

Publications (1)

Publication Number Publication Date
AR008618A1 true AR008618A1 (es) 2000-02-09

Family

ID=10795969

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP970102790A AR008618A1 (es) 1996-06-27 1997-06-25 PROCEDIMENTO PARA LA PREPARACIoN DE UNA FORMA SoLIDA COMPRIMIDA DE DOSIFICACIoN ORAL Y PROCEDIMIENTO PARA LA PREPARACIoN DE UN MATERIAL COMPACTADO DE GRANULACIoN GRUESA SIN COHESIoN ADECUADO PARA MÉTODOS ULTERIORES DE MOLIENDA Y COMPRESIoN ("COPRIMATE").
ARP070100474A AR059324A2 (es) 1996-06-27 2007-02-06 Una forma solida de dosificacion oral

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP070100474A AR059324A2 (es) 1996-06-27 2007-02-06 Una forma solida de dosificacion oral

Country Status (32)

Country Link
US (3) US6294197B1 (enExample)
EP (7) EP1767207A3 (enExample)
JP (5) JP2000506540A (enExample)
KR (6) KR101208430B1 (enExample)
CN (3) CN1475207B (enExample)
AR (2) AR008618A1 (enExample)
AT (3) ATE371449T1 (enExample)
BR (1) BR9709956A (enExample)
CA (2) CA2259148C (enExample)
CO (1) CO4870755A1 (enExample)
CY (1) CY2553B1 (enExample)
CZ (1) CZ296850B6 (enExample)
DE (3) DE69739642D1 (enExample)
DK (3) DK1767206T3 (enExample)
ES (3) ES2231873T3 (enExample)
GB (1) GB9613470D0 (enExample)
HU (1) HU229134B1 (enExample)
ID (1) ID17553A (enExample)
IL (2) IL127564A0 (enExample)
MY (3) MY123149A (enExample)
NO (2) NO317181B1 (enExample)
NZ (2) NZ333385A (enExample)
PE (1) PE87498A1 (enExample)
PL (2) PL188233B1 (enExample)
PT (3) PT1410797E (enExample)
RU (5) RU2294743C2 (enExample)
SI (2) SI0914119T1 (enExample)
SK (1) SK285902B6 (enExample)
TR (1) TR199802698T2 (enExample)
TW (1) TW473394B (enExample)
WO (1) WO1997049394A2 (enExample)
ZA (1) ZA975673B (enExample)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US20030045561A1 (en) * 2001-02-06 2003-03-06 Smithkline Beecham Corporation Method of treating isolated systolic hypertension
ZA991706B (en) * 1998-03-04 2000-10-03 Takeda Chemical Industries Ltd Sustained-release preparation for Aii Antagonist, production and use thereof.
KR100554924B1 (ko) 1998-05-18 2006-03-03 다케다 야쿠힌 고교 가부시키가이샤 구강내 붕괴 정제
RU2450813C2 (ru) * 1998-07-10 2012-05-20 Новартис Аг Гипотензивная комбинация валсартана и блокатора кальциевых каналов
RU2271809C2 (ru) 1998-12-23 2006-03-20 Новартис Аг Применение антагониста рецептора at-1 или модулятора рецептора ат-2 для лечения болезней, связанных с увеличением содержания рецепторов ат-1 или ат-2
CN101011390A (zh) 1999-01-26 2007-08-08 诺瓦提斯公司 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用
CA2360691A1 (en) * 1999-01-26 2000-08-03 Novartis Ag Use of angiotensin ii receptor antagonists for treating acute myocardial infarction
WO2001013900A2 (en) * 1999-08-24 2001-03-01 Medicure International Inc. Compositions for the treatment of cardiovascular diseases containing pyridoxal compounds and cardiovascular compounds
DE10066408B4 (de) * 2000-03-24 2010-03-18 3M Espe Dental Ag Verwendung feinkörniger Pulver für supragingivales Pulverstrahlen
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US20020132839A1 (en) * 2000-06-22 2002-09-19 Ganter Sabina Maria Tablet formulations comprising valsartan
AU2005200815B2 (en) * 2000-06-22 2008-01-17 Novartis Ag Solid valsartan pharmaceutical compositions
EP1296677A2 (en) * 2000-06-22 2003-04-02 Novartis AG Solid valsartan pharmaceutical compositions
CN100413852C (zh) 2000-07-19 2008-08-27 诺瓦提斯公司 缬沙坦的盐
PE20020617A1 (es) * 2000-08-22 2002-08-05 Novartis Ag Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
US20060089389A1 (en) 2000-08-22 2006-04-27 Malcolm Allison Combination
US8168616B1 (en) 2000-11-17 2012-05-01 Novartis Ag Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
CA2456034A1 (en) * 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Sustained-release medicines
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
DE10230272A1 (de) * 2002-07-05 2004-01-22 Solvay Pharmaceuticals Gmbh AT1-Rezeptorantagonisten zur Prävention von Folgeschlaganfällen
EP1382334A1 (en) * 2002-07-11 2004-01-21 Université de Picardie Jules Verne Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke
US7199144B2 (en) * 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
US20040242661A1 (en) * 2003-03-17 2004-12-02 Igor Rukhman Polymorphs of valsartan
EP1950204A1 (en) 2003-03-17 2008-07-30 Teva Pharmaceutical Industries Ltd. Amorphous form of valsartan
EP1556363A2 (en) * 2003-04-21 2005-07-27 Teva Pharmaceutical Industries Limited Process for the preparation of valsartan and intermediates thereof
US7378531B2 (en) * 2003-04-21 2008-05-27 Teva Pharmaceutical Industries Ltd Process for the preparation of valsartan
KR100882156B1 (ko) * 2003-08-08 2009-02-06 아지노모토 가부시키가이샤 나테글리니드 함유 제제
GB0325605D0 (en) * 2003-11-03 2003-12-10 Novartis Ag Combination of organic compounds
WO2005041941A2 (en) * 2003-11-03 2005-05-12 Zentiva, A.S. Valsartan containing formulation
JP2005187793A (ja) * 2003-12-24 2005-07-14 Rohm & Haas Electronic Materials Llc 改良された接着剤
WO2005082329A2 (en) * 2004-02-19 2005-09-09 Ranbaxy Laboratories Limited Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide
WO2005089720A1 (en) * 2004-03-10 2005-09-29 Ranbaxy Laboratories Limited Valsartan tablets and the process for the preparation thereof
JP4511550B2 (ja) 2004-09-02 2010-07-28 テバ ファーマシューティカル インダストリーズ リミティド オルメサルタンメドキソミルの調製法
PT2801354T (pt) * 2004-10-08 2017-06-05 Forward Pharma As Composições farmacêuticas de libertação controlada compreendendo um éster de ácido fumárico
US20080050605A1 (en) * 2004-10-15 2008-02-28 Rapp Knut M Pan Coating Process
EA012392B1 (ru) * 2004-12-24 2009-10-30 Крка, Д.Д. Ново Место Твердая фармацевтическая композиция, содержащая валсартан
EP1674080A1 (en) * 2004-12-24 2006-06-28 KRKA, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
FR2882260A1 (fr) * 2005-02-21 2006-08-25 Flamel Technologies Sa Forme pharmaceutique orale multimicroparticulaire a liberation modifiee d'antagonistes des recepteurs de l'angiotensine ii
NZ563759A (en) * 2005-05-31 2010-06-25 Mylan Lab Inc Compositions comprising nebivolol, a hydralazine compound and an isosorbide nitrate
US20070117987A1 (en) * 2005-07-05 2007-05-24 Viviana Braude Process for preparing valsartan
GB0513888D0 (en) * 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
US20080227836A1 (en) * 2005-10-31 2008-09-18 Lupin Ltd Stable Solid Oral Dosage Forms of Valsartan
RU2309732C1 (ru) 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
WO2007112288A2 (en) * 2006-03-23 2007-10-04 Mount Sinai School Of Medicine Cardiovascular composition and use the same for the treatment of alzheimers disease
CA2654408C (en) 2006-06-06 2018-05-08 Oleg Iliich Epshtein Medicinal agent for treating fatness, diabetes, and diseases associated with impaired glucose tolerance
GB0612540D0 (en) 2006-06-23 2006-08-02 Novartis Ag Galenical formulations of organic compounds
EP2043607A2 (en) * 2006-06-23 2009-04-08 Usv Limited Process for the preparation of micronized valsartan
EP1897537A1 (en) * 2006-09-04 2008-03-12 Novartis AG Composition comprising an angiotensin II receptor antagonist
PE20081364A1 (es) * 2006-09-04 2008-12-04 Novartis Ag Composicion farmaceutica que comprende valsartan
BRPI0716302A2 (pt) * 2006-10-30 2013-08-13 Hanall Pharmaceutical Co Ltd composiÇço farmacÊutica oral de liberaÇço atrasda por tempo de intervalo e mÉtodo para preparar um composiÇço farmacÊutica oral de liberaÇço atrasada por tempo de intervalo
WO2008064338A2 (en) * 2006-11-22 2008-05-29 Rubicon Research Pvt. Ltd. Valsartan formulation for pulsatile delivery
CA2681708A1 (en) * 2007-03-29 2008-10-09 Alembic Limited Valsartan tablet formulations
TR200703568A1 (tr) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formülasyonları
WO2009015880A1 (en) * 2007-07-31 2009-02-05 Cargill, Incorporated Direct compressible dextrose
GB0715628D0 (en) * 2007-08-10 2007-09-19 Generics Uk Ltd Solid valsartan composition
CN101396366B (zh) * 2007-09-25 2010-10-13 浙江华海药业股份有限公司 含缬沙坦的固体口服制剂及其制备方法
AR066168A1 (es) * 2007-09-28 2009-07-29 Novartis Ag Formulaciones galenicas de compuestos organicos
JP2011500577A (ja) 2007-10-09 2011-01-06 ノバルティス アーゲー バルサルタンの医薬製剤
DK2295035T3 (en) 2007-11-06 2016-08-29 Novartis Ag Double acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonists / blockers (arb) and neutral endopeptidase (nep) inhibitors
EP2067470A1 (en) * 2007-12-03 2009-06-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing valsartan and process for its preparation
JP2011507973A (ja) * 2007-12-31 2011-03-10 ルピン・リミテッド アムロジピンとバルサルタンとの医薬組成物
BRPI0907151A2 (pt) * 2008-02-28 2015-07-07 Novartis Ag Formas sólidas de dosagem oral de valsartan e métodos de produzir essas formilações
US20090226515A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
US20090226516A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Sartan compositions
CN102065847A (zh) * 2008-04-29 2011-05-18 韩诺生物制约株式会社 含有血管紧张素-ⅱ受体阻断剂的药物制剂
AU2009257174A1 (en) * 2008-06-09 2009-12-17 Dimerix Bioscience Pty Ltd Novel receptor hetero-dimers/-oligomers
KR101033975B1 (ko) * 2008-10-10 2011-05-11 이희엽 직접압축법을 이용한 발사르탄 함유 고형 경구 제형의 제조방법 및 이에 따라 제조된 고형 경구 제형
DE102008051783A1 (de) * 2008-10-17 2010-04-22 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Valsartan enthaltende Tablette
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
WO2010104485A2 (en) 2009-03-11 2010-09-16 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations
RU2398570C1 (ru) * 2009-04-17 2010-09-10 Илья Николаевич Медведев Способ снижения содержания микровезикул в крови при стабильной стенокардии напряжения i-ii функционального класса с артериальной гипертонией
WO2011027021A1 (en) * 2009-09-01 2011-03-10 Orion Corporation A method for the treatment of hypertension
KR101084783B1 (ko) * 2009-09-01 2011-11-22 삼성에스디아이 주식회사 이차 전지 및 그의 제조 방법
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
CN101897675B (zh) * 2010-02-10 2012-11-21 温士顿医药股份有限公司 含有凡尔沙坦或其药学上可接受的盐的固体剂型口服医药组成物
SI2536396T1 (sl) 2010-02-16 2017-01-31 KRKA, tovarna zdravil, d.d.,Novo mesto Postopek za pripravo oralnih trdnih odmernih oblik, ki obsegajo valsartan
AR083417A1 (es) 2010-10-14 2013-02-21 Novartis Ag Composiciones farmaceuticas que contienen un dgat1 inhibidor
JP5882796B2 (ja) 2011-03-31 2016-03-09 キヤノン株式会社 振動体の駆動方法、振動装置、該振動装置を有する駆動装置、及び光学機器
GB201116993D0 (en) * 2011-10-03 2011-11-16 Ems Sa Pharmaceutical compositions of antihypertensives
AU2012360935A1 (en) 2011-12-26 2014-07-17 Novartis Ag Tablets and dry-coated agents
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
JP6018420B2 (ja) * 2012-06-05 2016-11-02 ニプロ株式会社 アンジオテンシンｉｉ受容体拮抗薬およびサイアザイド系利尿薬を含む医薬組成物
KR101944085B1 (ko) * 2012-09-06 2019-01-30 한국콜마주식회사 발사르탄 함유 고형 경구제형 및 그 제조방법
JP2014062064A (ja) * 2012-09-21 2014-04-10 Ohara Yakuhin Kogyo Kk バルサルタン含有錠剤の製造方法
JP6238831B2 (ja) * 2014-04-25 2017-11-29 沢井製薬株式会社 バルサルタン含有錠剤及びその製造方法
JP6141472B2 (ja) * 2016-03-02 2017-06-07 大原薬品工業株式会社 バルサルタン含有錠剤の製造方法
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
EP3807898A1 (en) 2018-06-14 2021-04-21 AstraZeneca UK Limited Methods for treatment of hypertension with an angiotensin ii receptor blocker pharmaceutical composition
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3200039A (en) 1962-05-28 1965-08-10 Pfizer & Co C Non-granulated tablets with 20% sorbitol in a particle size of from about 100mu to about 2000mu
GB1422176A (en) 1973-05-05 1976-01-21 Beecham Group Ltd Pharmaceutical tablets
AU528098B2 (en) 1978-11-16 1983-04-14 Beecham Group Plc Analgesic tablet
US4353887A (en) 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
US4238485A (en) * 1979-10-29 1980-12-09 Merck & Co., Inc. Novel pharmaceutical compositions
EP0070127A3 (en) 1981-07-10 1983-08-17 Beecham Group Plc Tablets
US4543359A (en) * 1982-10-01 1985-09-24 Eaton Laboratories, Inc. Treating cardiac arrhythmias with dantrolene sodium
HU187215B (en) * 1983-01-26 1985-11-28 Egyt Gyogyszervegyeszeti Gyar Method for producing pharmaceutical product of high actor content and prolonged effect
US4609675A (en) * 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4743612A (en) * 1986-10-17 1988-05-10 Berlex Laboratories, Inc. Prodrug derivatives of the cardiotonic agent 4-ethyl-1,3-dihydro-5-(4-(2-methyl-1H-imidazol-1-yl)benzoyl)-2H-imidazol-2-one, composition containing them, and method of using them to treat cardiac failure
DE3705055A1 (de) * 1987-02-18 1988-09-01 Boehringer Ingelheim Kg Verwendung von 2-(3-fluor-4-methylphenylimino)-imidazolidin zur behandlung der koronaren herzkrankheit
JP2518854B2 (ja) * 1987-06-19 1996-07-31 旭化成工業株式会社 固形製剤の製法
DE3739779A1 (de) * 1987-11-24 1989-06-08 Beiersdorf Ag Pharmazeutische praeparate
SE506179C2 (sv) * 1989-01-23 1997-11-17 Ciba Geigy Ag Farmaceutisk lågkomposition av benazepril och ett tiaziddiuretikum
GB8909793D0 (en) 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation
DE122010000024I1 (de) * 1990-02-19 2010-07-08 Novartis Ag Acylverbindungen
JPH06501475A (ja) * 1990-09-28 1994-02-17 メルク　エンド　カンパニー　インコーポレーテッド イブプロフェン−利尿剤の組み合わせ
EP0553777B1 (en) * 1992-01-29 2002-04-24 Takeda Chemical Industries, Ltd. Fast dissolving tablet and its production
IL104755A0 (en) 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma
US5395627A (en) * 1992-09-04 1995-03-07 Akzo N.V. Pharmaceutical granulate
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
AU5449194A (en) 1992-10-26 1994-05-24 Merck & Co., Inc. Combinations of angiotensin-ii receptor antagonists and diuretics
CA2152795C (en) 1992-12-30 1999-02-16 Victor Louis King Readily available konjac glucomannan sustained release excipient
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
US5464854A (en) 1993-11-11 1995-11-07 Depadova; Anathony S. Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S.
AT401871B (de) * 1994-01-28 1996-12-27 Gebro Broschek Gmbh Verfahren zur herstellung von s(+)-ibuprofen- partikeln mit verbesserten fliesseigenschaften und deren verwendung zur arzneimittelherstellung
JP3534130B2 (ja) * 1994-03-01 2004-06-07 旭化成ケミカルズ株式会社 医薬品組成物
GB9404010D0 (en) * 1994-03-02 1994-04-20 Opt Tel Services Limited Telephone dialling monitoring and route selecting apparatus
CN1143908A (zh) * 1994-03-17 1997-02-26 西巴-盖尔基股份公司 利用哇尔沙通(valsartan)治疗糖尿病型肾病
GB9408117D0 (en) 1994-04-23 1994-06-15 Smithkline Beecham Corp Pharmaceutical formulations
DE19502065C2 (de) * 1995-01-14 1996-05-02 Prophyta Biolog Pflanzenschutz Pilzisolat mit fungizider Wirkung
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
FR2735365B1 (fr) * 1995-06-14 1997-09-05 Sanofi Sa Utilisation d'un antagoniste de l'angiotensine ii et d'un derive du benzofurane pour la preparation d'un medicament utile dans le traitement des affections cardiovasculaires
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
JP2011123241A (ja) * 2009-12-10 2011-06-23 Canon Inc 撮影システム

Also Published As

Publication number Publication date
EP1774967A1 (en) 2007-04-18
ATE276750T1 (de) 2004-10-15
EP1767206A3 (en) 2007-04-18
JP2012051948A (ja) 2012-03-15
HUP0203374A3 (en) 2004-06-28
PT1410797E (pt) 2007-12-03
RU2294743C2 (ru) 2007-03-10
RU2007100200A (ru) 2008-07-20
PL188233B1 (pl) 2004-12-31
NO20041287L (no) 2004-03-26
NO986056L (no) 1998-12-22
IL195339A0 (en) 2009-08-03
BR9709956A (pt) 1999-08-10
JP2014012747A (ja) 2014-01-23
EP1410797B1 (en) 2007-08-29
CN1133427C (zh) 2004-01-07
GB9613470D0 (en) 1996-08-28
NO986056D0 (no) 1998-12-22
CN1475207A (zh) 2004-02-18
AR059324A2 (es) 2008-03-26
RU2009115778A (ru) 2010-11-10
EP1767207A3 (en) 2007-04-18
SK285902B6 (sk) 2007-10-04
PE87498A1 (es) 1998-12-21
ES2231873T3 (es) 2005-05-16
AU724998B2 (en) 2000-10-05
KR20050092054A (ko) 2005-09-16
DK1410797T3 (da) 2007-10-15
KR20000022111A (ko) 2000-04-25
ATE371449T1 (de) 2007-09-15
ID17553A (id) 1998-01-08
CZ426998A3 (cs) 1999-03-17
EP1776953A1 (en) 2007-04-25
KR101161283B1 (ko) 2012-07-02
EP1410797A1 (en) 2004-04-21
AU3340297A (en) 1998-01-14
PL188271B1 (pl) 2005-01-31
KR20090099020A (ko) 2009-09-18
TW473394B (en) 2002-01-21
PL330709A1 (en) 1999-05-24
WO1997049394A2 (en) 1997-12-31
JP4969338B2 (ja) 2012-07-04
WO1997049394A3 (en) 2001-12-20
DE69738089T2 (de) 2008-05-21
HUP0203374A2 (hu) 2004-05-28
DE69730834T2 (de) 2005-10-06
TR199802698T2 (xx) 1999-04-21
RU2453306C2 (ru) 2012-06-20
HK1019858A1 (en) 2000-06-09
US20030035832A1 (en) 2003-02-20
NZ524346A (en) 2004-09-24
KR101208430B1 (ko) 2012-12-05
SI0914119T1 (en) 2005-04-30
IL127564A0 (en) 1999-10-28
KR20060079260A (ko) 2006-07-05
NZ333385A (en) 2000-09-29
JP2007238637A (ja) 2007-09-20
CN1232394A (zh) 1999-10-20
KR100618038B1 (ko) 2006-11-30
ES2290400T3 (es) 2008-02-16
EP1767206A2 (en) 2007-03-28
RU2203054C2 (ru) 2003-04-27
ZA975673B (en) 1997-12-29
CA2673462C (en) 2011-10-04
PT914119E (pt) 2005-02-28
CO4870755A1 (es) 1999-12-27
EP1767206B1 (en) 2009-10-28
US6485745B1 (en) 2002-11-26
CN1951372A (zh) 2007-04-25
CZ296850B6 (cs) 2006-07-12
RU2013113610A (ru) 2014-10-10
DE69738089D1 (de) 2007-10-11
PT1767206E (pt) 2010-01-27
ATE446749T1 (de) 2009-11-15
EP1767207A2 (en) 2007-03-28
ES2335683T3 (es) 2010-03-31
CN1475207B (zh) 2010-09-29
CA2259148A1 (en) 1997-12-31
NO331739B1 (no) 2012-03-12
CA2259148C (en) 2009-09-29
NO317181B1 (no) 2004-09-06
EP0914119A2 (en) 1999-05-12
DK1767206T3 (da) 2010-01-25
JP2000506540A (ja) 2000-05-30
EP0914119A3 (en) 2002-03-06
HK1060700A1 (en) 2004-08-20
EP0914119B1 (en) 2004-09-22
SK178498A3 (en) 1999-06-11
EP2055301A1 (en) 2009-05-06
CA2673462A1 (en) 1997-12-31
JP2003231634A (ja) 2003-08-19
CN1951372B (zh) 2011-03-23
DK0914119T3 (da) 2005-01-31
MY146868A (en) 2012-09-28
KR100792389B1 (ko) 2008-01-08
CY2553B1 (en) 2008-07-02
US6858228B2 (en) 2005-02-22
DE69739642D1 (de) 2009-12-10
DE69730834D1 (de) 2004-10-28
KR20080014149A (ko) 2008-02-13
SI1410797T1 (sl) 2008-08-31
US6294197B1 (en) 2001-09-25
MY123149A (en) 2006-05-31
MY156312A (en) 2016-01-29
HU229134B1 (en) 2013-08-28
KR20110063587A (ko) 2011-06-10

Similar Documents

Publication Publication Date Title
AR008618A1 (es) PROCEDIMENTO PARA LA PREPARACIoN DE UNA FORMA SoLIDA COMPRIMIDA DE DOSIFICACIoN ORAL Y PROCEDIMIENTO PARA LA PREPARACIoN DE UN MATERIAL COMPACTADO DE GRANULACIoN GRUESA SIN COHESIoN ADECUADO PARA MÉTODOS ULTERIORES DE MOLIENDA Y COMPRESIoN ("COPRIMATE").
RU2008109913A (ru) Твердые лекарственные формы валсатрана и амлодипина и способ их получения
RU2009102273A (ru) Твердые лекарственные формы валсартана, амлодипина и гидрохлортиазида и способ их получения
US5210079A (en) Treatment of chronic renal failure with imidazole angiotensin-II receptor antagonists
US5990148A (en) Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor
NO20061347L (no) Farmasoytisk formulering omfattende lanthanforbindelser
WO1992000067A2 (en) Treatment of chronic renal failure with imidazole angiotensin-ii receptor antagonists
EP0833622A1 (en) Compositions comprising a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
CA2224563A1 (en) Combination of a cyclooxygenase-2 inhibitor and a leukotriene b4 receptor antagonist for the treatment of inflammations
DK0881899T3 (da) Ibuprofen-doseringsform
RU2004118709A (ru) Составы, содержащие азитромицин, поддающиеся прямому прессованию
CL2008002829A1 (es) Combinacion farmaceutica de dosis oral fija que comprende aliskireno y valsartan; uso de la combinacion para tratar hipertension, angina, infarto al miocardio, arterioscleosis, nefropatia diabetica, insuficiencia renal, entre otras; metodos de preparacion de la combinacion en forma de bicapa y en forma se tableta sobre encapsulada.
JP2010534698A5 (enExample)
AR038143A1 (es) Agonistas del receptor 2 del factor liberador de la corticotropina
AR038145A1 (es) Composicion de politartrato
WO2001036630A3 (en) Triggering receptor involved in natural cytotoxicity mediated by human natural killer cells, and antibodies that identify the same
FR2729202A1 (fr) Materiaux de garniture synthetiques pour leur utilisation dans des presses a haute pression
PL371963A1 (en) Pharmaceutical composition comprising n- ((1-n-butyl-4-piperidinyl) methyl)-3, 4-dihydro-2h- (1, 3) oxazino (3, 2-a) indole-10-carboxamide or salt and process therefor comprising dry granulation
EA200300247A1 (ru) Фармацевтическая композиция, содержащая циталопрам
RU2010116530A (ru) Галеновые композиции алискирена
WO2007098686A1 (en) Andrographis extract formulations
WO2002072045A3 (fr) Composition solide contenant au moins 75% en poids de particules solides et au moins une huile liquide non volatile
US20050079221A1 (en) Ibuprofen narcotic composition and method for making same
TNSN07166A1 (en) Composition comprising vlp and amyloid-beta peptide
Chang et al. Effect of aggregate on fracture properties of high-performance concrete

Legal Events

Date Code Title Description
FG Grant, registration